PURPOSE: We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma. MATERIALS AND METHODS: 39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m² was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m² as an intravenous infusion on day 1, once every 3 weeks. RESULTS: Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild. CONCLUSION: The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.
PURPOSE: We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma. MATERIALS AND METHODS: 39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m² was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m² as an intravenous infusion on day 1, once every 3 weeks. RESULTS: Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild. CONCLUSION: The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.
Authors: U Vanhoefer; P Rougier; H Wilke; M P Ducreux; A J Lacave; E Van Cutsem; M Planker; J G Santos; P Piedbois; B Paillot; H Bodenstein; H J Schmoll; H Bleiberg; B Nordlinger; M L Couvreur; B Baron; J A Wils Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Shirish M Gadgeel; Anthony F Shields; Lance K Heilbrun; Samir Labadidi; Mark Zalupski; Ruth Chaplen; Philip A Philip Journal: Am J Clin Oncol Date: 2003-02 Impact factor: 2.339
Authors: A Ohtsu; N Boku; F Tamura; K Muro; Y Shimada; K Saigenji; S Akazawa; M Kitajima; R Kanamaru; T Taguchi Journal: Am J Clin Oncol Date: 1998-08 Impact factor: 2.339
Authors: W K Murphy; F V Fossella; R J Winn; D M Shin; H E Hynes; H M Gross; E Davilla; J Leimert; H Dhingra; M N Raber Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: P Chollet; P Schöffski; K Weigang-Köhler; J H M Schellens; H Cure; N Pavlidis; V Grünwald; R De Boer; J Wanders; P Fumoleau Journal: Eur J Cancer Date: 2003-06 Impact factor: 9.162
Authors: C M F Kruijtzer; H Boot; J H Beijnen; H L Lochs; F X Parnis; A S T Planting; J M G Pelgrims; R Williams; R A A Mathôt; H Rosing; M E Schot; H Van Tinteren; J H M Schellens Journal: Ann Oncol Date: 2003-02 Impact factor: 32.976
Authors: C Kollmannsberger; D Quietzsch; C Haag; T Lingenfelser; M Schroeder; J T Hartmann; W Baronius; V Hempel; M Clemens; L Kanz; C Bokemeyer Journal: Br J Cancer Date: 2000-08 Impact factor: 7.640
Authors: Hoon-Kyo Kim; Jun Suk Kim; Hun Mo Ryoo; Dong Gun Shin; Byoung Young Shim; Kyong Hwa Park; Sung Hwa Bae; Chi Hong Kim Journal: Cancer Res Treat Date: 2006-04-30 Impact factor: 4.679